~~<i id='53BD4B2167'><strike id='53BD4B2167'><tt id='53BD4B2167'><pre id='53BD4B2167'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：fashion 2025-09-27 18:53:52 - browse：65942

Photo illustration of a single pill on a large white field – opinion coverage from STAT — Adobe

This time last year, members of Congress were working around the clock to draft and pass the Inflation Reduction Act.

One of their goals was to address government spending on health care. But they specifically didn’t want to discourage research into rare disease treatments, so they exempted some of these so-called orphan drugs from the law.

Unfortunately, the exemptions aren’t working as intended. Unless Congress acts, the IRA threatens to unravel one of America’s greatest medical and public policy success stories: the explosion of new treatments for patients living with rare diseases.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： UnitedHealth’s Optum accused of antitrust violations in California

entertainment

focus

hotspot

leisure time

hotspot

AnnaMoneymaker/GettyImagesWASHINGTON—TheSupremeCourtwillthisMarchhearargumentscenteredonthegovernmen

WSS

Cigna, Humana reportedly in talks to merge

Woodcock on FDA’s accelerated approval and her next chapter

Takeda, Janssen join wearable maker to measure scratching

30 years of 'Listening to Prozac'

Despite FDA concern, risk that CAR

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

hotspot

hotspot

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

What we need to know about Arena Bioworks

Hepatitis C has a cure — but many Americans still lack access to it

SAMSHA loosens regulations on methadone treatment centers

ChatGPT in medicine: STAT answers readers' burning questions

Some dementia cases could be undiagnosed liver disease

Alkermes shareholders re

Even great ERs can’t make up for American health disparities

Psychedelics group wrestles with new pharma identity

Commercial surrogacy can be ethical, despite pope’s claims

focus

Organ aging and disease risk measured by new blood test

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Organ aging and disease risk measured by new blood test

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Vertex non

hotspot

hotspot

leisure time

hotspot